Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction

Journal of the American College of Cardiology

Volumn 73, Issue 19, 2019, Pages 2365-2383

  Greene, Stephen J ^a,b   Fonarow, Gregg C ^c   DeVore, Adam D ^a,b   Sharma, Puza P ^d   Vaduganathan, Muthiah ^e   Albert, Nancy M ^f   Duffy, Carol I ^d   Hill, C Larry ^a   McCague, Kevin ^d   Patterson, J Herbert ^g   Spertus, John A ^h   Thomas, Laine ^a   Williams, Fredonia B ⁱ   Hernandez, Adrian F ^a,b   Butler, Javed ^j  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g University of North Carolina   (United States)

^h SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

ⁱ Mended Hearts   (United States)

^j UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

dose; heart failure; medication; reduced ejection fraction; registry

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; HEMOGLOBIN; MINERALOCORTICOID ANTAGONIST;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG USE; EMPLOYMENT STATUS; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; HEART EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NEW YORK HEART ASSOCIATION CLASS; OUTPATIENT; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT REFUSAL; COMBINATION DRUG THERAPY; DOSE RESPONSE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85065023260     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.02.015     Document Type: Article

References (22)

1. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
2. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70 (2017), 776–803.
3. Yancy, C.W., Januzzi, J.L. Jr., Allen, L.A., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 71 (2018), 201–230.
4. Greene, S.J., Butler, J., Albert, N.M., et al. Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF Registry. J Am Coll Cardiol 72 (2018), 351–366.
5. Peri-Okonny, P.A., Mi, X., Khariton, Y., et al. Target doses of heart failure medical therapy and blood pressure: insights from the CHAMP-HF Registry. J Am Coll Cardiol HF 7 (2019), 350–358.
6. Gheorghiade, M., Albert, N.M., Curtis, A.B., et al. Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail 18 (2012), 9–17.
7. DeVore, A.D., Thomas, L., Albert, N.M., et al. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J 189 (2017), 177–183.
8. Fonarow, G.C., Albert, N.M., Curtis, A.B., et al. Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation 122 (2010), 585–596.
9. SOLVD Investigators Yusuf, S., Pitt, B., Davis, C.E., Hood, W.B., Cohn, J.N., Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991), 293–302.
10. Cohn, J.N., Johnson, G., Ziesche, S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991), 303–310.
11. Cohn, J.N., Tognoni, G., Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001), 1667–1675.
12. Young, J.B., Dunlap, M.E., Pfeffer, M.A., et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004), 2618–2626.
13. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353 (1999), 9–13.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999), 2001–2007.
15. Packer, M., Coats, A.J., Fowler, M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001), 1651–1658.
16. McMurray, J.J., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
17. Tahhan, A.S., Vaduganathan, M., Greene, S.J., et al. Enrollment of older patients, women, and racial and ethnic minorities in contemporary heart failure clinical trials: a systematic review. JAMA Cardiol 3 (2018), 1011–1019.
18. DeVore, A.D., Mi, X., Thomas, L., et al. Characteristics and treatments of patients enrolled in the CHAMP-HF Registry compared with patients enrolled in the PARADIGM-HF trial. J Am Heart Assoc, 7, 2018.
19. Bhagat, A.A., Greene, S.J., Vaduganathan, M., Fonarow, G.C., Butler, J., Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. J Am Coll Cardiol HF 7 (2019), 1–12.
20. Peterson, P.N., Rumsfeld, J.S., Liang, L., et al. Treatment and risk in heart failure: gaps in evidence or quality?. Circ Cardiovasc Qual Outcomes 3 (2010), 309–315.
21. Greene, S.J., Fonarow, G.C., Vaduganathan, M., Khan, S.S., Butler, J., Gheorghiade, M., The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol 12 (2015), 220–229.
22. Velazquez, E.J., Morrow, D.A., DeVore, A.D., et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 380 (2018), 539–548.